A number of other analysts have also recently weighed in on DNDN. Analysts at Jefferies Group (NYSE: JEF) initiated coverage on shares of Dendreon in a research note to investors on Tuesday. They set an “underperform” rating on the stock. Separately, analysts at Maxim Group initiated coverage on shares of Dendreon in a research note to investors on Friday, May 18th. They set a “sell” rating and a $5.00 price target on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Dendreon in a research note to investors on Wednesday, May 9th. They now have a $9.25 price target on the stock.
Dendreon traded down 2.99% on Wednesday, hitting $7.1299. Dendreon has a 52-week low of $6.46 and a 52-week high of $43.96. The company’s market cap is $1.053 billion.
Dendreon Corporation (Dendreon) is a biotechnology company focused on the discovery, development and commercialization of therapeutics that may improve cancer treatment options for patients.